Wells Fargo maintains Inspire Medical Systems at Equal-Weight, raises price target to $69 from $56

Wells Fargo raised its price target for Inspire Medical Systems to $69 from $56, maintaining an Equal-Weight rating. The new target implies a 2.7% upside from the last close. Recent analyst price targets range from $60 to $78.

Original reporting
Published Nov 3, 2026, 3:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 3:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wells Fargo maintains Inspire Medical Systems at Equal-Weight, raises price target to $69 from $56 — source image
Decision brief

The 30-second read

$INSPBullishLow
01

Why it matters

A higher target can attract incremental buyers and reduce downside expectations, but unchanged rating suggests limited urgency and likely smaller price follow-through than an upgrade.

02

Market read

Traders may use the target raise as a sentiment input, but it is not a standalone fundamental catalyst.

03

What to watch

The article does not include the thesis behind the target change, so traders may discount the move if it is driven by broad model assumptions rather than new company-specific fundamentals.

Relevance 4/10Novelty 4/10Timing: as of the analyst note publication date, for positioning ahead of subsequent analyst revisions

Background

The piece is an analyst note update: Wells Fargo keeps Inspire Medical Systems at Equal-Weight while increasing its price target.

Company-level read

Ticker impact

$INSPBullishMedium confidence
Context

Wells Fargo maintained Inspire Medical Systems at Equal-Weight and raised its price target to $69 from $56, implying modest upside from the Nov 2 close.

Expected impact

Likely mild upward bias as traders price in the higher target, with upside capped by the unchanged Equal-Weight stance.

Evidence & confidence

The article provides a specific, time-relevant price target change and an implied upside versus the prior close, but it is not a fundamental company event (no earnings, trial, or deal).

Market effects

Limited read-through to the broader medical device space because this is a single-name analyst target change without new clinical or regulatory data.

Minimal, as the catalyst is company-specific and not a macro release.

Low, since the update is tied to a US-listed equity and does not reference global policy or cross-border events.

Counterpoint

Because the rating stays Equal-Weight, the market may treat the target raise as incremental and focus instead on upcoming company catalysts (earnings, procedure demand, or trial/regulatory milestones).

Key entities

  • Inspire Medical Systems

    Subject of the analyst action, with Wells Fargo raising its price target while maintaining Equal-Weight.

  • Wells Fargo

    The brokerage issuing the maintained rating and revised price target.

Related articles

$INSPMedAI 8/10

Inspire (INSP) Q3 2026 Earnings Call Transcript

Inspire (INSP) reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3% sequentially. The company expects stable coding framework in 2027 and a new code in 2028, with strong adoption of Inspire V. Operating loss was $28.7M, and adjusted EPS was $0.14. The company is investing in patient flow optimization and expanding market reach. According to the company, they remain confident in their path to growth.

$INSPMed

Inspire: Q3 Earnings Snapshot

Inspire Medical Systems (INSP) reported a Q3 loss of $24.4M, or 84 cents per share, but adjusted earnings of 14 cents per share, beating estimates. Revenue was $206.7M, also topping forecasts. The company expects full-year earnings of $1.20-$1.40 per share and revenue of $850M-$860M.

$INSPMed

Inspire Medical Systems Q3 Earnings Call Highlights

Inspire Medical Systems (INSP) reported Q3 earnings, estimating coding and reimbursement challenges reduced results by $30M and may impact 2026 results by $120M. The company expects revenue growth in Q4 and low-single-digit growth in 2027, citing stable coding and investments. Inspire highlighted a new CPT code for its Inspire V device and ongoing development of Inspire VI. Management discussed clinical evidence supporting their therapy and plans to invest in patient access and education.

$INSPHighAI 8/10

Inspire Medical Q3 2026 slides: reimbursement clarity ahead, growth reset

Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3.0% sequentially. The company cited reimbursement challenges as the primary headwind. Shares rose 1.83% in after-hours trading. Inspire highlighted its market position and long-term growth potential, despite near-term slowdowns. The company expects full-year 2026 revenue of $850M-$860M, down from 2025 levels.